These 6 biotech stocks are promising takeover targets

"The appetite for M&A is still high," says Jared Holz, of the healthcare sector trading desk at Jefferies. "There are probably a dozen large cap pharma and biotech companies that are looking to augment their pipelines, and they know they can't do it internally."